<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Fortress Biotech Inc — News on 6ix</title>
<link>https://6ix.com/company/fortress-biotech-inc</link>
<description>Latest news and press releases for Fortress Biotech Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/fortress-biotech-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683567a978dffbe2df0f1048.webp</url>
<title>Fortress Biotech Inc</title>
<link>https://6ix.com/company/fortress-biotech-inc</link>
</image>
<item>
<title>Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-reports-2025-financial-results-and-recent-corporate-highlights-5</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-reports-2025-financial-results-and-recent-corporate-highlights-5</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review</description>
</item>
<item>
<title>Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotechs-subsidiary-cyprium-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-dollar205-million</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotechs-subsidiary-cyprium-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-dollar205-million</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc.</description>
</item>
<item>
<title>Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent-corporate-highlights-1</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent-corporate-highlights-1</guid>
<pubDate>Wed, 25 Mar 2026 20:01:00 GMT</pubDate>
<description>Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM)</description>
</item>
<item>
<title>Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 18,</description>
</item>
<item>
<title>UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/update-fortress-biotechs-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-dollar205-million</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/update-fortress-biotechs-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-dollar205-million</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc.</description>
</item>
<item>
<title>Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotechs-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-dollar205-million</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotechs-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-dollar205-million</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc.</description>
</item>
<item>
<title>Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/avenue-therapeutics-enters-into-exclusive-worldwide-license-agreement-for-atx-04-for-the-treatment-of-pompe-disease-1</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/avenue-therapeutics-enters-into-exclusive-worldwide-license-agreement-for-atx-04-for-the-treatment-of-pompe-disease-1</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme</description>
</item>
<item>
<title>Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-cyprium-therapeutics-announce-124500275</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-cyprium-therapeutics-announce-124500275</guid>
<pubDate>Tue, 13 Jan 2026 12:45:00 GMT</pubDate>
<description>Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration</description>
</item>
<item>
<title>Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-cyprium-therapeutics-announce-130000451</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-cyprium-therapeutics-announce-130000451</guid>
<pubDate>Mon, 15 Dec 2025 13:00:00 GMT</pubDate>
<description>New PDUFA Target Action Date of January 14, 2026 set by FDAMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the resubmission of the New Drug Application (“NDA”) for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. The resubmission has been accepted as a Class 1 re</description>
</item>
<item>
<title>Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-announces-publication-of-clinical-trial-results-assessing-the-impact-of-emrositm-dfd-29-on-microbial-flora-of-healthy-adults-in-the-journal-of-drugs-in-dermatology</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-announces-publication-of-clinical-trial-results-assessing-the-impact-of-emrositm-dfd-29-on-microbial-flora-of-healthy-adults-in-the-journal-of-drugs-in-dermatology</guid>
<pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
<description>Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up</description>
</item>
<item>
<title>Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-reports-third-quarter-133000207</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-reports-third-quarter-133000207</guid>
<pubDate>Fri, 14 Nov 2025 13:30:00 GMT</pubDate>
<description>Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Dotinurad, a next-generation URAT1 inhibitor, is advancing in two Phase 3 clinical trials with potential</description>
</item>
<item>
<title>Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights </title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics</description>
</item>
<item>
<title>Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling a</description>
</item>
<item>
<title>Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/avenue-therapeutics-announces-acquisition-of-subsidiary-baergic-bio-by-axsome-therapeutics-2</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/avenue-therapeutics-announces-acquisition-of-subsidiary-baergic-bio-by-axsome-therapeutics-2</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from AxsomeMIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic</description>
</item>
<item>
<title>Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-to-announce-third-quarter-2025-financial-results-on-november-12-2025</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-to-announce-third-quarter-2025-financial-results-on-november-12-2025</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET SCOTTSDALE, Ariz., Nov. 05,</description>
</item>
<item>
<title>Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-reports-combined-emrositm-dfd-29-phase-3-clinical-trial-efficacy-data-analysis-presented-at-the-2025-fall-clinical-dermatology-conference</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-reports-combined-emrositm-dfd-29-phase-3-clinical-trial-efficacy-data-analysis-presented-at-the-2025-fall-clinical-dermatology-conference</guid>
<pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
<description>FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United</description>
</item>
<item>
<title>Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-subsidiary-urica-therapeutics-123000313</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-subsidiary-urica-therapeutics-123000313</guid>
<pubDate>Tue, 21 Oct 2025 12:30:00 GMT</pubDate>
<description>MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor</description>
</item>
<item>
<title>Journey Medical Corporation to Participate in October 2025 Investor Conferences</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-to-participate-in-october-2025-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/journey-medical-corporation-to-participate-in-october-2025-investor-conferences</guid>
<pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
<description>SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage</description>
</item>
<item>
<title>Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-subsidiary-urica-therapeutics-120500484</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-subsidiary-urica-therapeutics-120500484</guid>
<pubDate>Wed, 01 Oct 2025 12:05:00 GMT</pubDate>
<description>Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica ma</description>
</item>
<item>
<title>Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101</title>
<link>https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-cyprium-therapeutics-announce-120000753</link>
<guid isPermaLink="true">https://6ix.com/company/fortress-biotech-inc/news/fortress-biotech-cyprium-therapeutics-announce-120000753</guid>
<pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
<description>MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) relating to the New Drug Application (“NDA”) for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. In December 2023, Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceut</description>
</item>
</channel>
</rss>